Figure 1.

Case selection flowchart. Depiction of case selection process, including cases filtered in the data for exclusions. ∗Included clinical culture sites: blood culture, bronchoalveolar lavage, protected bronchial brush washing, sputum culture, and tracheal aspirate. Patients with bloodstream and respiratory infection due to Stenotrophomonas maltophilia were counted in the bloodstream site of infection category. †Antimicrobials with activity against Stenotrophomonas 2 days prior to and 7 days after culture positivity were excluded. Known Stenotrophomonas-active agents that were excluded are erythromycin, moxifloxacin, ciprofloxacin, minocycline, tigecycline, doxycycline, eravacycline, ceftazidime, cefepime, ticarcillin-clavulanate, cefiderocol, colistin, and chloramphenicol. ‡Defined as receiving levofloxacin as empiric therapy (day –2 to –1 from culture positivity) and trimethoprim-sulfamethoxazole as targeted therapy and vice versa.